IMV Inc.

2:00 PM - 2:15 PM (EDT), Wednesday, October 23, 2019 ・ 2nd Floor
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck.
Ticker:
IMV
Exchange:
Nasdaq
Company Type:
Company Website:
Company HQ State:
Nova Scotia
Company HQ Country:
Canada
Year Founded:
2000
Main Therapeutic Focus:
Lead Product in Development:
DPX Survivac
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
CEO
IMV Inc.